Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $543.97, for a total value of $5,167,715.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,037,856.61. This trade represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Down 0.6%

Shares of NASDAQ UTHR opened at $541.83 on Wednesday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The firm has a market cap of $23.00 billion, a PE ratio of 20.00, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. The business has a fifty day simple moving average of $559.59 and a two-hundred day simple moving average of $526.79.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company posted $6.63 EPS. On average, research analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on UTHR shares. HC Wainwright raised their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Raymond James Financial began coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America boosted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its position in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. purchased a new position in United Therapeutics in the third quarter worth $317,617,000. Norges Bank acquired a new position in shares of United Therapeutics during the fourth quarter worth $293,418,000. Avoro Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.